Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Comprehensive Exploration of NK Cell Education in ADCC Triggered By a Monoclonal Antibody or a Bispecific Killer Engager Molecule (BiKE)

Caroline Leijonhufvud, Heinrich Schlums, Arwen Stikvoort, Michael Uhlin, Yenan T Bryceson, Mattias Carlsten

Blood (2022) 140 (Supplement 1): 8350.

https://doi.org/10.1182/blood-2022-166470

Published: 2022

Journal Articles

A Novel CD34-Specific T-Cell Engager Efficiently Depletes Stem Cells and Acute Myeloid Leukemia Cells in Vitro and In Vivo

Lucas C M Arruda, Liqing Jin, Melanie Lambert, Laura Sanchez Rivera, Renato Alvez, Tales Rocha de Moura, Carsten Mim, Rebecca Axelsson-Robertson, John E. Dick, Jonas Mattsson, Bjorn Onfelt, Mattias Carlsten, Michael Uhlin

Blood (2021) 138 (Supplement 1): 2861.

https://doi.org/10.1182/blood-2021-145278

Published: 2021

Journal Articles

Hypersialylation Protects Multiple Myeloma Cells from NK Cell-Mediated Immunosurveillance and This Can be Overcome By Targeted Desialylation Using a Sialyltransferase Inhibitor

John Daly, MSc, Subhashis Sarkar, PhD, Alessandro Natoni, PhD, Robert Henderson, MB BCh, Dawn Swan, Mattias Carlsten, MD PhD, Michael E O'Dwyer, MD

Blood (2019) 134 (Supplement_1): 138.

https://doi.org/10.1182/blood-2019-126613

Published: 2019

Journal Articles

Complete Remission and Signs of Immunoediting Following Haploidentical NK Cell Therapy in Refractory High-Risk MDS and AML Ell Therapy in Refractory High-Risk MDS and AML

Andreas T Björklund, MD PhD MSc, Mattias Carlsten, MD PhD, Ebba Sohlberg, PhD, Trevor Clancy, Lisa Liu, Mohsen Karimi, PhD, Sarah Cooley, MD, Jeffrey S. Miller, MD, Emma Watz, Björn Engelbrekt Wahlin, Marzia Palma, MD PhD, Lotta Hansson, Per Ljungman, Eva Hellstrom-Lindberg, MD PhD, Hans-Gustaf Ljunggren, Karl-Johan Malmberg, MD PhD

Blood (2017) 130 (Supplement 1): 4458.

https://doi.org/10.1182/blood.V130.Suppl_1.4458.4458

Published: 2017

Journal Articles

A Naive NK Cell Repertoire in the Circulation of Haploidentical Stem Cell Donors Pre Mobilization Predicts Rejection of Cord Myeloid Cells in Patients Undergoing Combined Haploidentical and Unrelated Cord Blood HSCT

Mattias Carlsten, MD, PhD, Robert N. Reger, Ritesh Kotecha, Enkhtsetseg Purev, Xin Tian, Roger Kurlander, Georg Aue, Richard W. Childs

Blood (2016) 128 (22): 2199.

https://doi.org/10.1182/blood.V128.22.2199.2199

Published: 2016

Journal Articles

Ex Vivo Expanded NK Cells Mediate Highly Efficient and Rapid Killing of Ewing Sarcoma Cells Through Degranulation with Tumor Cytotoxicity Controlled by the NKG2D, DNAM-1, and NKp30 NK Receptors

Amrita D. Karambelkar, B.S., Robert N. Reger, B.S., Mattias Carlsten, MD, PhD, Richard W. Childs, MD

Blood (2015) 126 (23): 1894.

https://doi.org/10.1182/blood.V126.23.1894.1894

Published: 2015

Journal Articles

mRNA Transfection of NK Cells with Gain-of-Function CXCR4 As a Novel Method to Enhance the Homing of Adoptively Transferred NK Cells to the Bone Marrow for the Treatment of Hematological Malignancies

Emily R. Levy, Robert N. Reger, B.S., Mattias Carlsten, MD, PhD, Richard W. Childs, MD

Blood (2015) 126 (23): 3089.

https://doi.org/10.1182/blood.V126.23.3089.3089

Published: 2015

Journal Articles

ER-Stress-Induced Suppression of HLA-E on Bortezomib-Evading Malignant Plasma Cells Dramatically Enhances Their Susceptibility to NK Cell Killing: Identification of an Achilles Heel in Myeloma Cells That Can be Utilized to Prevent Disease Relapse Following Bortezomib Treatment

Mattias Carlsten, MD, PhD, Ali Namazi, MD, Robert N. Reger, B.S., Maria Berg, Richard W. Childs, MD

Blood (2015) 126 (23): 4296.

https://doi.org/10.1182/blood.V126.23.4296.4296

Published: 2015

Journal Articles

Treatment of Ex Vivo Expanded NK Cells with Daratumumab F(ab')2 Fragments Protects Adoptively Transferred NK Cells from Daratumumab-Mediated Killing and Augments Daratumumab-Induced Antibody Dependent Cellular Toxicity (ADCC) of Myeloma

Elena Cherkasova, PhD, Luis Espinoza, MD PhD, Ritesh Kotecha, Robert N. Reger, B.S., Maria Berg, Georg Aue, Ricardo M. Attar, PhD, A Kate Sasser, Mattias Carlsten, MD, PhD, Richard W. Childs, MD

Blood (2015) 126 (23): 4244.

https://doi.org/10.1182/blood.V126.23.4244.4244

Published: 2015

Journal Articles

Clinical-Grade mRNA Electroporation of NK Cells: A Novel and Highly Efficient Method to Genetically Reprogram Human NK Cells for Cancer Immunotherapy

Mattias Carlsten, MD PhD, Linhong Li, Su Su, MD PhD, Maria Berg, Robert Reger, Madhusudan V. Peshwa, Richard Childs, MD

Blood (2014) 124 (21): 2153.

https://doi.org/10.1182/blood.V124.21.2153.2153

Published: 2014

Journal Articles

Early and Transient Microchimerism Associated with Complete Remission after Adoptively Transferred Haploidentical NK Cells Against High Risk Myelodysplastic Syndrome and Refractory Acute Myeloid Leukemia

Andreas T Björklund, MDPhD, Mattias Carlsten, MD PhD, Marie Schaffer, PhD, Lisa Liu, MD, Sarah A. Cooley, MD MS, Jeffrey S. Miller, MD, Emma Watz, MD, Marzia Palma, MD PhD, Lotta Hansson, MD PhD, Björn E Wahlin, MD PhD, Lars Möllgård, MDPhD, Hans Hagglund, MD PhD, Pontus Blomberg, PhD, Per T. Ljungman, MD PhD, Eva Hellström-Lindberg, MD PhD, Hans-Gustaf Ljunggren, MD PhD, Karl-Johan Malmberg, MD, PhD

Blood (2014) 124 (21): 1120.

https://doi.org/10.1182/blood.V124.21.1120.1120

Published: 2014

Journal Articles

A Suppressive Microenvironment in Acute Myeloid Leukemia Induces Global Alteration of T and NK Cell Profiles - Evidence for Immune-Editing Effect By Leukemia

Sawa Ito, MD, John Barrett, MD, Bipin N. Savani, MD, Madan Jagasia, MBBS, MS, Eolia Brissot, Samantha Miner, Nancy F. Hensel, Fariba Chinian, M.S., Keyvan Keyvanfar, BS, Minoo Battiwalla, MD MS, Michael R Savona, MD, Sanjay Mohan, MD, Mattias Carlsten, MD PhD, Pawel Muranski, MD, Stephen A. Strickland, MD MSCI

Blood (2014) 124 (21): 1047.

https://doi.org/10.1182/blood.V124.21.1047.1047

Published: 2014

Journal Articles

Ultra-Low Dose IL-2 Safely Expands Regulatory T Cells and CD56 bright NK Cells in Healthy Volunteers: Towards Safer Stem Cell Donors?

Sawa Ito, MD, Minoo Battiwalla, MD, MS, J. Joseph Melenhorst, Ph.D., Mattias Carlsten, MD Ph.D, Angelique Biancotto, PhD, Ena Wang, M.D., Zhi Xie, Ph.D., Pawel Muranski, MD, Matthew J. Olnes, MD, PhD, Kazushi Tanimoto, MD, Paula Schum, R.N., Shira Perl, MD, Howard Dickler, MD, J. Philip McCoy, PhD, Thomas Hughes, Pharm D, Leodayan Bojanowski, DNP, CIP, RN, Nancy F. Hensel, BS, Neal S. Young, MD, A. John Barrett, MD

Blood (2012) 120 (21): 3283.

https://doi.org/10.1182/blood.V120.21.3283.3283

Published: 2012

Journal Articles

Optimizing Lentiviral Transduction of Human Natural Killer Cells

Su Su, MD, PhD, Dawn M Betters, Ph.D, Muthalagu Ramanathan, MD, Keyvan Keyvanfar, BS, Aleah Smith, Xingmin Feng, PhD, Elissa Furutani, Mattias Carlsten, MD Ph.D, Andreas Lundqvist, PhD, Richard Childs, MD

Blood (2011) 118 (21): 4714.

https://doi.org/10.1182/blood.V118.21.4714.4714

Published: 2011

Journal Articles

A Phase I Trial of Adoptively Transferred Ex-Vivo Expanded Autologous Natural Killer (NK) Cells Following Treatment with Bortezomib to Sensitize Tumors to NK Cell Cytotoxicity

Robert N Reger, Maria Berg, Andreas Lundqvist, PhD, Theresa Donohue, MHS, PA-C, Mattias Carlsten, MD Ph.D, Dawn M Betters, Ph.D, Lisa Cook, RN, BSN, Catalina Ramos, RN, BSN, Sophia Grasmeder, RN, BSN, OCN, Su Su, MD, PhD, David Stroncek, MD, Jeremy Pantin, MD, Keyvan Keyvanfar, BS, Cristian A. Carvallo, MD, Hahn Khuu, MD, Richard Childs, MD

Blood (2011) 118 (21): 1001.

https://doi.org/10.1182/blood.V118.21.1001.1001

Published: 2011

Journal Articles

A Phase II Trial of IPH2101 (anti-KIR mAb) in Smoldering Multiple Myeloma

Neha Korde, MD, Jane Trepel, Mattias Carlsten, MD Ph.D, Adriana Zingone, MD, PhD, Rene Costello, Mary Ann Yancey, RN, Marcia Mulquin, RN, Irina Maric, MD, Katherine Calvo, MD, PhD, Prashant Ramesh Tembhare, MD, Constance Yuan, MD, PhD, Maryalice Stetler-Stevenson, MD, PhD, Min-Jung Lee, MD, Sylvia Alarcon, George Carter, PA, Richard Childs, MD, Ola Landgren, MD, PhD

Blood (2011) 118 (21): 2944.

https://doi.org/10.1182/blood.V118.21.2944.2944

Published: 2011

NARROW

Comprehensive Exploration of NK Cell Education in ADCC Triggered By a Monoclonal Antibody or a Bispecific Killer Engager Molecule (BiKE)

A Novel CD34-Specific T-Cell Engager Efficiently Depletes Stem Cells and Acute Myeloid Leukemia Cells in Vitro and In Vivo

Hypersialylation Protects Multiple Myeloma Cells from NK Cell-Mediated Immunosurveillance and This Can be Overcome By Targeted Desialylation Using a Sialyltransferase Inhibitor

Complete Remission and Signs of Immunoediting Following Haploidentical NK Cell Therapy in Refractory High-Risk MDS and AML Ell Therapy in Refractory High-Risk MDS and AML

A Naive NK Cell Repertoire in the Circulation of Haploidentical Stem Cell Donors Pre Mobilization Predicts Rejection of Cord Myeloid Cells in Patients Undergoing Combined Haploidentical and Unrelated Cord Blood HSCT

Ex Vivo Expanded NK Cells Mediate Highly Efficient and Rapid Killing of Ewing Sarcoma Cells Through Degranulation with Tumor Cytotoxicity Controlled by the NKG2D, DNAM-1, and NKp30 NK Receptors

mRNA Transfection of NK Cells with Gain-of-Function CXCR4 As a Novel Method to Enhance the Homing of Adoptively Transferred NK Cells to the Bone Marrow for the Treatment of Hematological Malignancies

ER-Stress-Induced Suppression of HLA-E on Bortezomib-Evading Malignant Plasma Cells Dramatically Enhances Their Susceptibility to NK Cell Killing: Identification of an Achilles Heel in Myeloma Cells That Can be Utilized to Prevent Disease Relapse Following Bortezomib Treatment

Treatment of Ex Vivo Expanded NK Cells with Daratumumab F(ab')2 Fragments Protects Adoptively Transferred NK Cells from Daratumumab-Mediated Killing and Augments Daratumumab-Induced Antibody Dependent Cellular Toxicity (ADCC) of Myeloma

Clinical-Grade mRNA Electroporation of NK Cells: A Novel and Highly Efficient Method to Genetically Reprogram Human NK Cells for Cancer Immunotherapy

Early and Transient Microchimerism Associated with Complete Remission after Adoptively Transferred Haploidentical NK Cells Against High Risk Myelodysplastic Syndrome and Refractory Acute Myeloid Leukemia

A Suppressive Microenvironment in Acute Myeloid Leukemia Induces Global Alteration of T and NK Cell Profiles - Evidence for Immune-Editing Effect By Leukemia

Ultra-Low Dose IL-2 Safely Expands Regulatory T Cells and CD56 bright NK Cells in Healthy Volunteers: Towards Safer Stem Cell Donors?

Optimizing Lentiviral Transduction of Human Natural Killer Cells

A Phase I Trial of Adoptively Transferred Ex-Vivo Expanded Autologous Natural Killer (NK) Cells Following Treatment with Bortezomib to Sensitize Tumors to NK Cell Cytotoxicity

A Phase II Trial of IPH2101 (anti-KIR mAb) in Smoldering Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only